Abstract: Objective : To compare the efficacy and side effects with three different neoadjuvant chemotherapy regimens for the treatment of breast cancer. Methods : Six-eight patients with stage Ⅱ、Ⅲ breast cancer were divided into three groups at random, and received FEC, ET or NE regimen every 3-4 weeks for 2 cycles. Clinical responses in the breast and lymph nodes were assessed after 2 cycles of neoadjuvant chemotherapy. Results : For primary tumors of breast, the overall response rate (RR) was 50% (12/24) in FEC arm and 79% (19/24, P<0.05) in ET arm and 75% (15/20, P<0.05) in N E arm respectively. There were only 2 cases obtained pathologic complete response in N E arm and no progressive disease in three groups,and a higher proportion of RR was in stage Ⅱ rather than that in stage Ⅲin three treatment groups. For all clinically involved auxilliary lymph nodes, 50% (12/24) in FEC arm and 67% (16/24, P<0.05) in ET arm and 60% (12/20, P<0.05) in NE arm were not palpable after 2 cycles neoadjuvant chemotherapy respectively. The major toxicities, including leukopenia, gastroenteric reactions, were similar in three groups,but alopecia was more severe and arthralgia, myalgia, neurotoxicity, and flushing of face were unique feature in ET regimens. Neurotocity and venous varsculitis were more obvious in N E regimens relatively. Conclusions : Neoadjuvant chemotherapy with three different regimens were all effective to primary tumors and axillary metastatic lymph nodes in breast cancer,and side effects were well tolerable. Better effects and more side effects have been observed in ET arm and NE arm than those in FEC arm.